 |
Recombinant human insulin-like growth factor-I |
|---|---|
| Trade Name | |
| Orphan Indication | Post-poliomyelitis syndrome |
| USA Market Approval | USA |
| USA Designation Date | 1995-10-13 00:00:00 |
| Sponsor | Teva Branded Pharmaceutical Product R&D;, Inc.;41 Moores Road;Frazer, Pennsylvania, 19355 |
